• Vivus Inc., of Mountain View, Calif., reported net product revenues of $41,000 from prescriptions of newly approved obesity drug Qsymia (phentermine/topiramate) shipped from certified pharmacies to patients. The drug, approved in July, was made available starting Sept. 17.